Author

A. Marcello

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 1 Bioengineering· 1 Microbiology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Research Focus:drug response / drug discovery· 2 Research Focus:host-pathogen & immune response· 2 Organism:human· 2

Frequent Co-Authors

A. M. Martin· 1 shared A. Yero· 1 shared C. Shang· 1 shared D. Lembo· 1 shared D. Martin· 1 shared D. Pupo· 1 shared E. Mastrangelo· 1 shared E. Schneider· 1 shared

Activity by Year

2020-2021 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 16 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperBiochemistry

A. M. Martin

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

In vitro rapid inactivation of SARS-CoV-2 by visible light photocatalysis using boron-doped bismuth oxybromide

L. Ling, T. Carletti, Z. Cheng, R. Wang, Y. Ren, P. Westerhoff, C. Shang, A. Marcello, S. Chen

This study demonstrates that boron-doped bismuth oxybromide rapidly inactivates SARS-CoV-2 under visible light and in the dark, outperforming conventional photocatalysts.

bioRxiv · Mar 9, 2021 · PreprintBioengineering

Combined in silico docking and in vitro antiviral testing for drug repurposing identified lurasidone and elbasvir as SARS-CoV-2 and HCoV-OC43 inhibitors

M. Milani, M. Donalisio, R. M. Bonotto, E. Schneider, I. Arduino, F. Boni, D. Lembo, A. Marcello, E. Mastrangelo

The paper identifies lurasidone and elbasidone as inhibitors of SARS-CoV-2 and HCoV-OC43 through in silico docking and in vitro testing.

bioRxiv · Nov 12, 2020Pharmacology & Toxicology

The low-density lipoprotein receptor-related protein-1 is essential for Dengue virus infection

V. Huerta Galindo, A. M. Martin, M. Sarria, O. Guirola, A. Yero, Y. Ramos, D. Pupo, D. Martin, A. Marcello, G. Chinea

This paper identifies LRP1 as a new receptor for Dengue virus entry, showing it binds the viral envelope protein and inhibits infection, suggesting it as a potential drug target.

bioRxiv · Jun 10, 2020Biochemistry

Repurposing of Miglustat to inhibit the coronavirus Severe Acquired Respiratory Syndrome SARS-CoV-2

S. Rajasekharan, R. Milan Bonotto, Y. Kazungu, L. Nascimento Alves, M. Poggianella, P. Martinez Orellana, N. Skoko, S. Polez, A. Marcello

This study shows that Miglustat inhibits SARS-CoV-2 by targeting glucosidases, reducing viral proteins and infectious virus release at clinically achievable concentrations.

bioRxiv · May 18, 2020 · PreprintMicrobiology